| The potential role of aripiprazole augmentation for major depressive disorder with anxious distress in naturalistic treatment setting |
Kyung Ho Lee  1,2, Tae Sun Han 3, Changsu Han 4, Won-Myong Bahk 3, Soo Jung Lee 3, Ashwin A Patkar5, Prakash S Masand6, Chi-Un Pae 2,3,* |
| 1Department of Dermatology, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea, 2Cell Death Disease Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, 3Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea, 4Department of Psychiatry, Korea University, College of Medicine, Seoul, Republic of Korea, 5Department of Psychiatry and Behavioral Sciences, Rush University Medical Center, Chicago, IL, USA, 6Duke-NUS Medical School, Singapore |
|
Abstract
Objective: This study tried to observe clinical benefit of aripiprazole augmentation (ARPA) treatment for major depressive disorder with anxious distress (MDDA) in routine practice.
Methods: Retrospective chart review (N=41) was conducted for clinical benefit of ARPA in patients with MDDA in routine practice. The primary endpoint was the mean change of Hamilton Anxiety Rating scale (HAMA) total scores from baseline to the endpoint. Additional secondary endpoints were also retrieved.
Results: The changes of primary endpoint HAMA(t=5.731, -4.6, P=0.001), and secondary endpoints including Hamilton Depression Rating scale (HAMD, t=4.284, -3.4, P<0.001), CGI-CB (-0.9, t=1.821, P=0.026), and Clinical Global Impression Score-Severity (CGI-S, t=3.556, -0.4, P<0.001) scores were also significantly improved during the study. No significant adverse events were observed.
Conclusion: This study has shown additional benefit of ARPA treatment for MDDA patients in routine practice. However, adequately-powered and well-controlled studies are necessary for generalization of the present findings.
|
| Accepted Manuscript [Submitted on 2023-06-15, Accepted on 2023-08-13] |
|